Eli Lilly (LLY) reported pivotal phase 3 results for retatrutide showing class-leading weight loss of up to 26.1% at 80 weeks and over 30% at 104 weeks in higher-BMI participants, alongside broad improvements in key cardiometabolic risk markers, further strengthening its GLP-1 franchise leadership and differentiation in obesity therapeutics, Wolfe Research tells investors in a research note. Reatrutide sets a new bar for next-generation therapies to differentiate, the firm adds. The firm maintains an Outperform rating and $1,350 price target on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s retatrutide Triumph-1 study a ‘clean win’, says RBC Capital
- Eli Lilly reports retatrutide meets primary endpoint in TRIUMPH-1 study
- Eli Lilly Raises $8.9 Billion in Debt Offering
- Eli Lilly (LLY) Acquires Engage Biologics for $202 Million
- Eli Lilly acquires Engage Biologics for up to $202M in cash